Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Equillium, Inc.NASDAQ: EQ
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $5.31M (cash outflow) fell 38.6% year over year, behind the +36.2% change in trailing-twelve-month net income. Sequentially, it rose 40.7% from the prior quarter. Over 3 fiscal years it compounded at -28.9% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$17.04M (-23.9%) for the fiscal year ending Dec 2026, a slowdown from the +177.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.31M+40.7% QoQ
- Last fiscal yearDec 2025
- -$22.4M+177.6% YoY
- LTMMar 2026
- -$19.06M+36.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -38.6% | +5.2% | +43.8 pp |
| 1 year | +177.6% | -23.9% | -201.6 pp |
| 3-year CAGR | -28.9% | +5.3% | +34.3 pp |
| 5-year CAGR | -1.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (22.4M) USD
- Year-over-year change
- -177.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.4M) | -177.6% |
| FY2024 | 2024-12-31 | (8.07M) | +39.5% |
| FY2023 | 2023-12-31 | (13.34M) | +78.6% |
| FY2022 | 2022-12-31 | (62.43M) | -59.9% |
| FY2021 | 2021-12-31 | (39.05M) | — |
Net Income vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 net income of $19.06M is the 8th largest of the 10 companies compared; the peer median is $24.54M.
- Its year-over-year change of +36.2% is the 4th highest of 10, against a peer median of +1.8%.
- Over three fiscal years its annual growth of -28.9% compares with a peer median of -10.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| LTM Mar 2026 | $9.22M | -26.0% | +130.2% | — | |
| Peer median (excluding EQ) | $24.54M | +1.8% | -10.4% | 899.5% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.05M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| Deferred Income Tax | 554K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.41M | 4.84M | 4M | 3.75M | 2.32M |
| Change in Working Capital | 1.7M | 19K | (2.55M) | 842K | (2.32M) |
| Accounts Receivables | 0 | (2.84M) | (897K) | 3.74M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | 2.51M | 723K | (2M) | (1.94M) |
| Other Working Capital | 3.28M | 349K | (2.37M) | (898K) | (380K) |
| Other Non-Cash Items | 237K | 48.72M | (10.03M) | (15.69M) | (469K) |
| Operating Cash Flow | (32.08M) | (8.73M) | (21.78M) | (19.03M) | (22.75M) |
| Capital Expenditures | (57K) | (279K) | (50K) | (85K) | (48K) |
| Acquisitions (Net) | 0 | 700K | 0 | 0 | 12K |
| Purchases of Investments | (32.99M) | (14.96M) | (54.71M) | (17.6M) | 0 |
| Sales of Investments | 60.46M | 33.23M | 50M | 31.5M | 4.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 27.41M | 18.68M | (4.76M) | 13.81M | 4.46M |
| Debt Repayment | 0 | (1.43M) | (9.13M) | 0 | 0 |
| Common Stock Issued | 29.91M | 214K | 0 | 164K | 30.43M |
| Common Stock Repurchased | 0 | 0 | (260K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.15M | 0 | 165K | 0 | 0 |
| Financing Cash Flow | 31.06M | (1.22M) | (9.23M) | 164K | 30.43M |
| Effect of Forex Changes | (2K) | 5K | (118K) | (83K) | 47K |
| Net Change in Cash | 26.38M | 8.74M | (35.89M) | (5.13M) | 12.19M |
| Free Cash Flow | (32.14M) | (9.01M) | (21.83M) | (19.11M) | (22.79M) |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.